Galectin Therapeutics Faces Regulatory Hurdles Despite Financial Support

Galectin Therapeutics shares are trading lower after regulatory challenges with the FDA necessitated further discussions on belapectin's clinical trial design, despite securing a $10 million credit line to cover upcoming expenditures.